Sign in Subscribe
COVID-19

Researchers Develop Cellular Therapy for High-Risk COVID-19 Patients

Strategic Insights

— 1 min read

Researchers at Thomas Jefferson University in Philadelphia have made new findings in the development of cellular therapy for high-risk patients with COVID-19. The study, published in Blood Advances, explores the use of allogeneic SARS-CoV-2-specific cytotoxic T lymphocytes (CTLs) as a potential treatment for severe cases of the virus. According to the research, treatment with these CTLs may enhance cellular immunity in high-risk patients, providing a safe and direct mechanism for treatment.

Key Takeaways:

  • The study enrolled 30 high-risk ambulatory patients with COVID-19, with 12 receiving a single infusion of allogeneic SARS-CoV-2-specific CTLs.
  • The patients who received CTLs showed significant improvement in symptoms, with 88% and 99% viral elimination from baseline at 4 and 14 days after infusion, respectively.
  • The CTLs did not interfere with the development of endogenous anti-SARS-CoV-2 humoral or cellular responses.
  • T-cell receptor beta analysis showed persistence of donor-derived SARS-CoV-2-specific CTLs through the end of the 6-month follow-up period.
  • The study found that interventional patients showed consistent symptom improvement 2 to 3 days after infusion, while observational patients showed more variable improvement.
  • The researchers concluded that SARS-CoV-2-specific CTLs are a potentially feasible cellular therapy for high-risk patients with COVID-19.

Statistics:

  • 30 high-risk ambulatory patients with COVID-19 were enrolled in the phase 1 trial.
  • 12 interventional patients received a single infusion of allogeneic SARS-CoV-2-specific CTLs.
  • 88% and 99% viral elimination from baseline was observed at 4 and 14 days after infusion, respectively.
  • No dose-limiting toxicities were observed at any dosing level.
  • Patients who received CTLs showed significant improvement in symptoms, with 100% symptom resolution at 6 months.

Sources:

  • Safety and feasibility of third-party cytotoxic T lymphocytes for high-risk patients with COVID-19. Blood Advances, 2024, 8(15).
  • https://doi-org.sdpl.idm.oclc.org/10.1182/bloodadvances.2024013344
  • Our news editors report that more information may be obtained by contacting Dolores Grosso, 1Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, PA, United States.

Read more